

Sub C<sup>6</sup>  
A1

23. (Once amended) A method of delivering a drug to a patient in need thereof, comprising administering a therapeutically or prophylactically effective amount of the drug in a formulation comprising a porous matrix [formed of] which comprises a wetting agent and microparticles of the drug, wherein the microparticles have a mean diameter between about 0.1 and 5  $\mu\text{m}$  and a total surface area greater than about 0.5  $\text{m}^2/\text{mL}$ , and wherein the [dry] porous matrix [is in a dry powder form having] has a TAP density less than or equal to 1.0  $\text{g/mL}$  and/or [having] has a total surface area of greater than or equal to 0.2  $\text{m}^2/\text{g}$  and is in the form of a dry powder.

A2

25. (Once amended) The method of claim 24 wherein the parenteral route is selected from the group consisting of [intravenous,] intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration.

A3

32. (Once amended) The method of claim 23 wherein the formulation is [a dry powder] suitable for pulmonary administration.

Please add the following new claims:

Sub C<sup>6</sup>  
Cont  
A4

--33. The method of claim 23 wherein the dry powder form of the porous matrix has a TAP density less than or equal to 1.0  $\text{g/mL}$ --

--34. The method of claim 23 wherein the dry powder form of the porous matrix has a total surface area of greater than or equal to 0.2  $\text{m}^2/\text{g}$ --